Medical Analysis

Comprehensive Clinical Evaluation of Myeloperoxidase MPO Staining Methodology and Pathological Diagnostic Principles

Advanced Pathological Insights into Myeloperoxidase MPO Staining and Immune Defense Functions

Myeloperoxidase (MPO) is a critical heme-peroxidase enzyme found predominantly within the azurophilic granules of neutrophils [1, 16]. Additionally, monocytes and certain specialized macrophage subpopulations contain very small amounts of myeloperoxidase [1, 2]. This specialized enzyme plays a major role in microbial killing via an oxidative burst, protecting the host against diverse invading pathogens [1, 2]. Beyond acute host defense, neutrophil-derived myeloperoxidase has been increasingly recognized for playing an important role in cancer development and progression [3]. MPO has been directly implicated in tumor initiation through the active support of a hypermutagenic environment [3]. Moreover, cancer progression is heavily influenced by the presence of MPO, which is involved in the tight regulation of tumor growth, apoptosis, cell migration, and metastasis [3]. Emerging scientific studies also suggest that myeloperoxidase might actively regulate adaptive immunity in various cancer settings [2, 3].

Molecular Structure and Biochemical Characteristics of MPO Enzymes

Myeloperoxidase functions structurally as a 150 kDa dimeric enzyme composed of two identical monomers [10]. Each monomer consists of a heavy polypeptide chain (H-chain, approximately 59 kDa) and a light polypeptide chain (L-chain, approximately 14.5 kDa) [10]. Each monomer contains a unique, covalently linked heme prosthetic group along with a structural calcium ion [10]. The light chains are heavily glycosylated and contain the primary heme active site [10]. Conversely, the heavy chains are linked together by a cysteine bridge, and the entire protein structure is extensively glycosylated, which profoundly influences its biochemical properties and complex interactions with other physiological molecules [10].

Core Physiological and Non-Canonical Functions of MPO

The multifaceted biological functions of myeloperoxidase span key immunological and pathological mechanisms [2, 3]. Through generating hypochlorous acid and other powerful oxidants within the innate immune system, MPO successfully manages to kill invading pathogens, including bacteria, fungi, and parasites [1, 2]. However, this mechanism exhibits a dual role by contributing significantly to both the protective immune response and localized tissue damage [3]. Its core microbial activity centers on the robust production of reactive oxygen species (ROS) designed to destroy pathogens [1, 2]. Furthermore, non-canonical functions include modulating neutrophil activation, directing cellular trafficking, promoting the formation of neutrophil extracellular traps (NETs), and driving activity implicated in chronic inflammatory conditions like cardiovascular disease [4, 17, 18].

Clinical Indications and Diagnostic Utility

Myeloperoxidase levels and expression patterns can be utilized to help diagnose and monitor critical clinical conditions such as systemic inflammation, acute infection, and various malignancies [4, 5, 12]. Clinicians should note that the specialized MPO blood test is a relatively new diagnostic modality and is not yet universally available across all routine clinical laboratories [7, 19].

Analytical Methods for Detection and Gold Standard Assays

Laboratory medicine employs several distinct methods of detection for evaluating myeloperoxidase [11, 19]:

• Immunohistochemistry [12]

• MPO Staining [11]

• ANCA (Indirect immunofluorescence) – ELISA [11, 19]

Despite various technical limitations including low susceptibility, vulnerability to rapid metabolism, and a time-consuming sample work-up, 3-chlorotyrosine (3-Cl-Tyr)—formed via the chlorination of tyrosine by hypochlorous acid (HOCl) or related chloramines—is universally considered the gold standard to detect myeloperoxidase activity in complex biological samples [19].

Specimen Collection and Laboratory Processing Protocols

Proper sample collection is paramount for obtaining accurate diagnostic results [12, 13]:

• Blood Collection: Collect 3.0 ml of whole blood directly into a plain tube with a red cap [11].

• Serum Separation: Separate the serum fraction from cellular components as early as possible [11].

• Storage: Store the processed sample safely at room temperature [11].

• Tissue Samples: Utilize paraffin blocks prepared from formalin-fixed tissue samples [12, 13].

• Smear Preparation: Prepare high-quality, well-distributed peripheral blood smears or bone marrow smears [13, 14].

Normal Reference Ranges and Risk Stratification for MPO Levels

Smoking status significantly influences baseline biomarker values, as smokers tend to have higher MPO levels than non-smokers [7, 11]. Risk stratification based on quantitative plasma concentration parameters includes [7, 11]:

• Lower Risks: 469 – 539 pmol/L [7, 11]

• Higher Risks: greater than or equal to 539 pmol/L [7, 11]

Comprehensive Pathological Causes of High Myeloperoxidase

Elevated MPO levels or abnormal tissue expression are associated with a diverse spectrum of severe medical pathologies [4, 20]:

• Cardiovascular: Coronary artery diseases, unstable angina, acute myocardial infarction, and atherosclerosis [4, 5, 9].

• Inflammatory Bowel Disease: Ulcerative colitis and Crohn’s disease [20].

• Autoimmune Diseases: Lupus arthritis, rheumatoid arthritis, and multiple sclerosis [20].

• Cancers: Leukemias, lymphomas, lung metastasis, and breast cancer progression [12, 20].

• Vasculitides: Microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (EGPA) [20].

Immunohistochemistry Significance and Diagnostic Signatures

The diagnostic interpretation of MPO immunohistochemistry relies on precise cellular localization patterns and quantitative thresholds [12, 15].

Clinical Precautions Advised for Patients with High MPO

To mitigate risks associated with elevated myeloperoxidase levels, clinicians recommend several vital lifestyle and therapeutic interventions [4, 7]:

• Consume a heart-healthy diet rich in fresh fruits, vegetables, and whole grains that remains low in overall fat [4, 7].

• Maintain an optimal, healthy weight-to-height ratio [7].

• Achieve strict and consistent blood pressure control [7].

• Stop smoking immediately to lower baseline systemic inflammation [4, 7].

• Incorporate regular physical activities into your daily routine [7].

• Collaborate closely with your healthcare provider to aggressively reduce low-density lipoprotein (LDL) cholesterol levels [4, 7].

Prognostic Significance in Oncology and Cardiology

In hematological malignancies, particularly acute myeloblastic leukemia variant M1, the low MPO group with a heterogeneous cell population is less likely to achieve complete remission (CR) with standard chemotherapy [12, 14]. Conversely, the high MPO group demonstrating a higher complete remission rate suggests a more pure biological entity within myeloblastic leukemias [12, 14]. In cardiovascular medicine, a single initial measurement of plasma myeloperoxidase independently predicts the early risk of myocardial infarction, as well as the composite risk of major adverse cardiac events (MACE) throughout the ensuing 30-day and 6-month follow-up periods [5, 7].

Principles and Reagent Preparation for Cytochemical MPO Staining

Cytochemical staining requires well-prepared peripheral blood smears or bone marrow smears [13, 14]. The core diagnostic principle involves detecting the myeloperoxidase enzyme inside myeloid cells through a targeted chemical reaction that triggers a visible color change [11, 14]. During this reaction, the active MPO enzyme catalyzes hydrogen peroxide to oxidize a specialized chromogen substrate—such as benzidine or 3,3′-diaminobenzidine (DAB)—forming an insoluble visible precipitate (typically brown or black) that highlights cells containing the enzyme [11, 14]. This assists clinical laboratories in identifying myeloid lineage cells within blood and bone marrow samples, which is particularly valuable for diagnosing and classifying acute myeloid leukemia (AML) and differentiating it from acute lymphoblastic leukemia (ALL) when lineage ambiguity arises in blastic leukemias [12, 14].

To prepare essential reagents [11]:

• Formalin Ethanol Fixative: Add 10 ml of 40% formaldehyde to 90 ml of 95% ethanol and mix thoroughly [11].

• Working DAB Substrate Solution: Add 20 microliters of Reagent A (DAB Chromogen) to 500 microliters of Reagent B (DAB Diluent) inside a dropper bottle [11].

Step-by-Step Procedure of Cytochemical MPO Staining

Executing manual cytochemical staining requires strict adherence to sequential laboratory steps [11, 14].

Limitations and Diagnostic Pitfalls of MPO Testing

Myeloperoxidase evaluations are subject to several technical and clinical limitations that can induce false-positive or false-negative results, including insufficient overall specificity and potential diagnostic uncertainty [8, 11]. Because of these inherent technical hurdles, MPO assays should not be utilized as the sole standalone determinant for establishing a definitive diagnosis [8, 11]. Furthermore, genetic or acquired MPO deficiency leads to an increased susceptibility to specific opportunistic infections, while elevated MPO levels consistently signal excessive, harmful systemic inflammation [8, 11].

For Non-Medicos

What Is Myeloperoxidase MPO?

Myeloperoxidase (MPO) is a special protective enzyme found inside white blood cells that helps your immune system fight off harmful bacteria and germs [1, 2].

Why Do Doctors Test MPO Levels?

Doctors check MPO levels in blood tests or tissue samples to help diagnose infections, severe inflammation, heart attack risks, and certain types of blood cancers like leukemia [4, 5, 12].

How Can You Manage High MPO Levels?

You can help keep MPO and inflammation levels down by quitting smoking, eating a healthy low-fat diet, exercising regularly, and managing your blood pressure and cholesterol [4, 7].

References:

1. Klebanoff, S. J. (2005). Myeloperoxidase: friend and foe. Journal of Leukocyte Biology, 77(5), 598-625.

2. Aratani, Y. (2018). Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Archives of Biochemistry and Biophysics, 640, 47-52.

3. Nauseef, W. M. (2014). Myeloperoxidase: therapeutic target and frequent innocent bystander. Pharmacology & Therapeutics, 141(3), 326-339.

4. Nicholls, S. J., & Hazen, S. L. (2005). Myeloperoxidase and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(6), 1102-1111.

5. Baldus, S., Heeschen, C., Meinertz, T., Zeiher, A. M., Eiserich, J. P., Münzel, T., … & Hamm, C. W. (2003). Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 108(12), 1440-1445.

6. Hazen, S. L. (2009). Myeloperoxidase and plaque vulnerability. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(5), 629-637.

7. Schindhelm, R. K., van der Zwan, L. P., Sorop, O., van den Born, B. J., Koopman, M. G., Tauleigne, A., … & Sorokin, A. (2009). Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?. Clinical Chemistry, 55(8), 1462-1470.

8. Kutter, D., Devaquet, P., Vanderstockt, J., Stomp, J. M., & Thoman, V. (2000). Consequences of total and partial myeloperoxidase deficiency: a report of 3 cases. Acta Haematologica, 104(1), 10-15.

9. Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine, 352(16), 1685-1695.

10. Arnhold, J. (2004). Properties, functions, and kinetic of myeloperoxidase. Acta Biochimica Polonica, 51(2), 293-308.

11. Ladda, D. (2026). Myeloperoxidase (MPO) Clinical Assay and Diagnostic Manual. Diagnopedia.

12. Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., … & Jaffe, E. S. (2016). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th ed.). IARC Press.

13. Orazi, A., & Hasserjian, R. P. (2022). Bone Marrow Pathology (5th ed.). Wolters Kluwer.

14. Bain, B. J. (2010). Leukaemia Diagnosis (4th ed.). Wiley-Blackwell.

15. Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S., Stein, H., & Jaffe, E. S. (2011). The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117(19), 5019-5032.

16. Borregaard, N., & Cowland, J. B. (1997). Granules of the neutrophils. Blood, 89(10), 3503-3521.

17. Papayannopoulos, V. (2018). Neutrophil extracellular traps in immunity and disease. Nature Reviews Immunology, 18(2), 134-147.

18. Metzler, K. D., Goosmann, C., Lubojemska, A., Zychlinsky, A., & Papayannopoulos, V. (2014). A myeloperoxidase-containing complex regulates neutrophil elastase activity and neutrophil extracellular trap formation. Cell Reports, 8(3), 883-896.

19. Kooter, A. J., van der Zwan, L. P., Lever, M., Smulders, Y. M., & Teerlink, T. (2010). 3-Chlorotyrosine as a marker for myeloperoxidase activity in vivo: analytical and clinical aspects. Clinical Chemistry and Laboratory Medicine, 48(1), 13-21.

20. Kumar, V., Abbas, A. K., & Aster, J. C. (2020). Robbins & Cotran Pathologic Basis of Disease (10th ed.). Elsevier.

FAQ’s:

• What is myeloperoxidase?
  A heme-peroxidase enzyme found in neutrophil azurophilic granules playing a key role in microbial killing.

• What is the MPO structure?
  A 150 kDa dimeric enzyme composed of heavy and light chains with heme groups.

• What are the primary functions?
  It generates oxidants for innate immune defense, microbial killing, and contributes to tissue inflammation.

• How is MPO measured?
  Detection methods include immunohistochemistry, MPO staining, enzyme assays, ELISA, and 3-chlorotyrosine quantification.

• What samples are required?
  Samples include whole blood in plain tubes, separated serum, tissue paraffin blocks, and smears.

• What are normal MPO ranges?
  Lower risk ranges are 469 to 539 pmol/L, while higher risks are 539 pmol/L or greater.

• What causes high MPO?
  Causes include coronary artery disease, inflammatory bowel disease, autoimmune arthritis, leukemias, and vasculitides.

• How is MPO staining performed?
  It uses substrates like DAB and hydrogen peroxide to form a visible brown precipitate in cells.

• What are MPO test limitations?
  Limitations include potential false results, insufficient specificity, and susceptibility to technical interferences.

• What is its prognostic significance?
  Plasma levels independently predict myocardial infarction risk, and expression helps classify acute myeloid leukemia.

Top-Rated Related Tests on Diagnopedia

• C-Reactive Protein (hs-CRP) Test